Skip to content

prognosis prediction and precise treatment strategies of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children

prognosis prediction and precise treatment strategies of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500103218
Enrollment
Unknown
Registered
2025-05-27
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children

Interventions

Experimental group A for 8 years old and over:Doxycycline oral with low-dose methylprednisolone IV
Experiment Group A for under 8 years old:Azithromycin with low-dose methylprednisolone
Experiment Group C for under 8 years old:Doxycycline oral
Experiment Group B for under 8 years old:Azithromycin with medium-dose methylprednisolone IV
Experimental group B for 8 years old and over:Doxycycline oral with medium-dose methylprednisolone IV

Sponsors

Children's Hospital,Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 16 Years

Inclusion criteria

Inclusion criteria: 1.MPP diagnostic criteria: A diagnosis can be made based on medical history, clinical symptoms, signs, and imaging findings, as well as meeting one of the following positive laboratory diagnostic criteria: (1) MP antibody titer increases by four times or more during the recovery phase compared to the acute phase; (2) MP culture positive or MP-DNA or RNA positive. 2.Macrolide-unresponsive M. pneumoniae pulmonary (MUMPP) was defined when children with MPP exhibit persistent fever and no improvement or worsening in clinical signs and pulmonary imaging after 72 hours of standard macrolide treatment. 3.The child himself/herself or his/her guardian signs the informed consent to participate in this study;

Exclusion criteria

Exclusion criteria: 1.patients with primary or secondary immune deficiency/dysfunction, congenital heart disease, chronic liver or kidney disease, oncologic disorders, connective tissue disease, chronic lung disease; 2.patients with evidence of mixed infection; 3.patients with incomplete medical records;

Design outcomes

Primary

MeasureTime frame
adverse drug reaction;Proportion of refractory Mycoplasma pneumoniae pneumonia;

Secondary

MeasureTime frame
days of fever;Improvement in chest imaging;days of hospitalisation;Improvement of inflammatory indicators;

Countries

China

Contacts

Public ContactMengyao Li

Children's Hospital,Zhejiang University School of Medicine

11918393@zju.edu.cn+86 17816872462

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026